One day, patients may be able to monitor their body’s response to cancer therapy just by having their blood drawn. A new study, led by Amy Herr, faculty engineer in the Biological Systems & Engineering Division, has taken an important step in that direction by measuring a panel of cancer proteins in rare, individual tumor cells that float in the blood. She says, “Microfluidic design was key in this study.” Read more in Berkeley News.
Was this page useful?
Send
